Why Juno Therapeutics Jumped 12% In September
What: This clinical-stage biotech company is researching T-cell cancer therapies. JCAR 015 for lymphoma & leukemia. Various others in early stage trials for leukemia & lymphoma. Shares jumped 12.1% in September. Presented at Morgan Stanley’s Global Healthcare Conference on September 16.
So What: Reengineering immune system’s T-cells. Using chimeric antigen receptor (CAR) approach to allow T-cells to bind to and kill cancer cells. Potential FDA filing in late 2016/early 2017. 10 drug candidates in human trials by 1H2016. Collaborating with Celgene.
So what continued…
So what continued… JCAR 015: 87% complete response/remission rate in relapsing/recurring adult acute lymphoblastic leukemia. JCAR 017: 91% complete response/remission rate in relapsing/recurring pediatric acute lymphoblastic leukemia.
Now what: JCAR 015: Phase 2 pivotal trial ongoing. Began in Q3 2015. Scheduled to complete in 2017.
Now what continued: Needs to confirm prior findings. Watch safety data. Focus on rates of cytokine response syndrome. 23% rate in prior studies. Remember, this is a clinical stage company without revenue and without products on the market. Suitable only for the most risk tolerant of investors.
The next billion-dollar iSecret. The Apple Watch was locked away deep within Apple's famous design lab, and the company did everything in its power to keep its game changer a secret. But the secret is out, and best of all, our analysts have discovered a "roundabout way" to invest in the gadget... for just a fraction the price of AAPL stock....To see our free report on these stocks, just click here now.